Contact Us
Find A Doctor

Wet AMD Eyedrop Treatment Clinical Trial

Study Title

A Phase 2b dose-evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration

Enrollment Status:

Closed to Enrollment


The purpose of this study is to evaluate how tolerable, safe, and effective it is to give Pazopanib eye drops to adults with Wet AMD compared to Ranibizumab injections.


Ages Eligible for Study: 50 years old and older

Genders Eligible for Study: Both

Inclusion Criteria

  • Subject has the diagnosis of ACTIVE Wet (Exudative) AMD.

  • Must have had at least three prior injections of Lucentis, Macugen or Avastin for treatment for the Wet AMD.

  • Aged 50 to 75 years.

  • Relatively good general medical health.


Contact Us

Dr. Richard Rosen, Principal InvestigatorTel: (212) 979-4284

Katy Tai, Research ManagerTel: (212) 979-4251

Address310 E. 14th StreetNew York, NY 10003

View all locations